Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery
Top Cited Papers
Open Access
- 1 August 2006
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 5 (8) , 1909-1917
- https://doi.org/10.1158/1535-7163.mct-06-0141
Abstract
Nanotechnology refers to the interactions of cellular and molecular components and engineered materials—typically, clusters of atoms, molecules, and molecular fragments into incredibly small particles—between 1 and 100 nm. Nanometer-sized particles have novel optical, electronic, and structural properties that are not available either in individual molecules or bulk solids. The concept of nanoscale devices has led to the development of biodegradable self-assembled nanoparticles, which are being engineered for the targeted delivery of anticancer drugs and imaging contrast agents. Nanoconstructs such as these should serve as customizable, targeted drug delivery vehicles capable of ferrying large doses of chemotherapeutic agents or therapeutic genes into malignant cells while sparing healthy cells. Such “smart” multifunctional nanodevices hold out the possibility of radically changing the practice of oncology, allowing easy detection and then followed by effective targeted therapeutics at the earliest stages of the disease. In this article, we briefly discuss the use of bioconjugated nanoparticles for the delivery and targeting of anticancer drugs. [Mol Cancer Ther 2006;5(8):1909–17]Keywords
This publication has 51 references indexed in Scilit:
- Folate-receptor-targeted delivery of doxorubicin nano-aggregates stabilized by doxorubicin–PEG–folate conjugateJournal of Controlled Release, 2004
- The dawning era of polymer therapeuticsNature Reviews Drug Discovery, 2003
- Chemical Approaches to Triggerable Lipid Vesicles for Drug and Gene DeliveryAccounts of Chemical Research, 2003
- Phase I Trial of Intraperitoneal Injection of the E1B-55-kd-Gene-Deleted Adenovirus ONYX-015 (dl1520) Given on Days 1 Through 5 Every 3 Weeks in Patients With Recurrent/Refractory Epithelial Ovarian CancerJournal of Clinical Oncology, 2002
- Cremophor ELEuropean Journal Of Cancer, 2001
- Pharmacokinetic characteristics and therapeutic effects of mitomycin C-dextran conjugates after intratumoural injectionJournal of Controlled Release, 1998
- Kinetic analysis of receptor-mediated endocytosis (RME) of proteins and peptides: use of RME as a drug delivery systemJournal of Controlled Release, 1996
- Targeting behavior of rat monoclonal IgG antibodies in vivo: role of antibody isotype, specificity and the target cell antigen densityEuropean Journal of Immunology, 1991
- Antigen density on target cells determines the immunosuppressive potential of rat IgG2b monoclonal antibodiesEuropean Journal of Immunology, 1989
- Structure and properties of pharmacologically active polymersJournal of Polymer Science: Polymer Symposia, 1975